Fecilax100gm

Aflibercept is a recombinant fusion protein acting as a VEGF inhibitor, prescribed with FOLFIRI to treat metastatic colorectal cancer resistant to oxaliplatin regimens.

Indicated in combination with FOLFIRI for patients with metastatic colorectal cancer (mCRC) resistant to or progressed following an oxaliplatin-containing regimen.

Cytotoxic Chemotherapy / Anti-angiogenic agent

VEGF Inhibitor & Recombinant Fusion Protein

Aflibercept functions as a decoy receptor binding to VEGF-A and PlGF, preventing them from activating VEGFR-1 and VEGFR-2 receptors, thus suppressing neovascularization and vascular permeability.

Inhibits angiogenesis and tumor growth by neutralizing VEGF-A and PlGF ligands required for endothelial cell activation.

4 mg/kg as an intravenous infusion over 1 hour every 2 weeks. Do not administer as an IV push or bolus.

Dilute in 0.9% Sodium Chloride or 5% Dextrose. Administer as an IV infusion over 1 hour using a 0.2 micron polyethersulfone filter. Do not mix with other drugs in the same IV line.

Consult the oncologist immediately to reschedule the infusion as soon as possible.

Common: Leukopenia, diarrhea, neutropenia, proteinuria, AST/ALT elevation, stomatitis, fatigue, thrombocytopenia, hypertension, weight decrease, epistaxis, abdominal pain, and dysphonia.

Monitor for fistula formation, hypertensive crisis, arterial thromboembolic events, proteinuria, severe diarrhea, and Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Delay if neutrophils < 1.5 x 10^9/L.

Known hypersensitivity to aflibercept or any components of the formulation.

No clinically important pharmacokinetic interactions found with irinotecan/SN-38 or 5-FU. Do not combine with other IV drugs in the same line.

Not applicable as it is administered intravenously.

Pregnancy Category C. Embryotoxic and teratogenic in animal studies. Effective contraception required during treatment and for 3 months after last dose.

Pregnancy Category: C — always consult a doctor before taking during pregnancy.

Discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in pediatric patients have not been established.

Patients ≥65 years experienced higher rates of diarrhea, dizziness, asthenia, weight loss, and dehydration; require closer monitoring.

No dose adjustment recommended for mild-to-moderate hepatic or renal impairment based on population PK analyses. Severe impairment data unavailable.

No reported cases of overdose. Doses > 7 mg/kg every 2 weeks lack safety data. Provide supportive care.

Store in refrigerator at 2° to 8°C. Keep vial in original carton to protect from light. Do not freeze.

Aflibercept (Recombinant Fusion Protein)

Question: What is Aflibercept used for? Answer: Aflibercept is used in combination with FOLFIRI chemotherapy for the treatment of metastatic colorectal cancer (mCRC) that has progressed after oxaliplatin-based therapy. Question: How is Aflibercept administered? Answer: It is administered as an intravenous (IV) infusion over 1 hour every 2 weeks. It should never be given as an IV push or bolus. Question: Is blood pressure and kidney monitoring necessary during treatment? Answer: Yes, regular monitoring of blood pressure and urine protein levels is required, as Aflibercept can cause hypertension and proteinuria. Question: Can Aflibercept be taken during pregnancy or family planning? Answer: No, it should not be used during pregnancy. Highly effective contraception must be used during treatment and for at least 3 months after the final dose.